Advertisement
RESEARCH ARTICLE
Sensory neuron cultures derived from adult db/db mice as a simplified model to study type-2 diabetes-associated axonal regeneration defects
Cristian De Gregorio, Fernando Ezquer
Disease Models & Mechanisms 2021 14: dmm046334 doi: 10.1242/dmm.046334 Published 22 January 2021

Handling Editor: Steven J. Clapcote

ABSTRACT

Diabetic neuropathy (DN) is an early common complication of diabetes mellitus (DM), leading to chronic pain, sensory loss and muscle atrophy. Owing to its multifactorial etiology, neuron in vitro cultures have been proposed as simplified systems for DN studies. However, the most used models currently available do not recreate the chronic and systemic damage suffered by peripheral neurons of type-2 DM (T2DM) individuals. Here, we cultured neurons derived from dorsal root ganglia from 6-month-old diabetic db/db-mice, and evaluated their morphology by the Sholl method as an easy-to-analyze readout of neuronal function. We showed that neurons obtained from diabetic mice exhibited neuritic regeneration defects in basal culture conditions, compared to neurons from non-diabetic mice. Next, we evaluated the morphological response to common neuritogenic factors, including nerve growth factor NGF and Laminin-1 (also called Laminin-111). Neurons derived from diabetic mice exhibited reduced regenerative responses to these factors compared to neurons from non-diabetic mice. Finally, we analyzed the neuronal response to a putative DN therapy based on the secretome of mesenchymal stem cells (MSC). Neurons from diabetic mice treated with the MSC secretome displayed a significant improvement in neuritic regeneration, but still reduced when compared to neurons derived from non-diabetic mice. This in vitro model recapitulates many alterations observed in sensory neurons of T2DM individuals, suggesting the possibility of studying neuronal functions without the need of adding additional toxic factors to culture plates. This model may be useful for evaluating intrinsic neuronal responses in a cell-autonomous manner, and as a throughput screening for the pre-evaluation of new therapies for DN.

INTRODUCTION

Diabetes mellitus (DM) is a multifactorial chronic disease characterized by a sustained hyperglycemic status. According to the International Diabetes Federation, 463 million people worldwide suffer from DM. Type-2 diabetes (T2DM), which is the most common type of diabetes, represents over 90% of total diabetes cases (International Diabetes Federation, 2019). DM has also been associated with several clinical complications affecting the heart, kidney, retina, vascular system and nervous system (Forbes and Cooper, 2013).

Diabetic neuropathy (DN) is the earliest and most prevalent chronic complication of diabetes, affecting up to 50% of DM patients (Argoff et al., 2006). Distal symmetric polyneuropathy is the most common form of DN (which normally occurs in a ‘stocking and glove’ distribution) and is proposed to reflect the dying-back of the longest peripheral nerve fibers in upper and lower limbs (Feldman et al., 2019). Patients afflicted with DN perceive a significant reduction in life quality due to sensitivity loss, chronic pain and muscle atrophy (Vincent et al., 2004), which are associated with a high risk of developing diabetic foot ulcerations and limb amputation (Volmer-Thole and Lobmann, 2016).

As DN has no available cure, the current management has been focused on improving glycemia control and promoting a healthy lifestyle. However, this is extremely difficult to achieve, as most diabetic patients do not follow the treatments. Additionally, strict glucose control seems to have only a partial effect in reducing DN progression in T2DM patients (Feldman et al., 2019). Neuropathic pain is normally treated with palliative drugs, such as anti-epileptics, antidepressants and opioids, but side effects mean they are not recommended as long-term treatments (Boulton et al., 2005). The highly complex and multifactorial etiology of DN has hindered the generation of comprehensive treatments. The current experimental strategies to treat or prevent DN aim to block the mechanisms involved in its development, including inhibition of several metabolic pathways, control of oxidative stress, reduction of chronic inflammation, stimulation of vasculogenesis and administration of neuroprotective factors (Pittenger and Vinik, 2003; Schratzberger et al., 2001; Shi et al., 2013a,b; Zhou and Zhou, 2014). Even though these treatments have generated promising results in experimental models of DM, none of these therapies have been effective when translated at the clinical level, suggesting the necessity for developing new models and identifying new therapeutic targets for DN (Muller et al., 2008).

Different animal models of DM have been used to study the pathogenesis of DN; for example, streptozotocin-induced or genetic-induced diabetic rodents on normal or high-calorie dietary regimes (O'brien et al., 2014; Reuter, 2007; Sullivan et al., 2007). However, the complexity of in vivo models has inherent limitations for studying molecular events and signal transduction pathways. Alternative in vitro model systems enable the evaluation of the relative contribution of specific cell types in the peripheral nervous system (PNS) to DN pathogenesis, in a controlled extracellular environment (Sango et al., 2006). Furthermore, in vitro cultures may be useful for throughput assays for the pre-screening of new potential therapeutic molecules that could prevent or reduce morphological, functional, or electrophysiological defects associated with hyperglycemia exposition (Melli and Höke, 2009; Vincent and Feldman, 2007). Additionally, in vitro cultures offer the advantage of reducing the number of animals needed, as the tissue obtained from one animal could be used to evaluate many different experimental conditions.

Several studies regarding the culture of neonatal rodent cells have shown that high glucose levels promote neuronal reactive oxygen species (ROS) production, mitochondrial dysfunction, neurite outgrowth defects and cell death in dorsal root ganglion (DRG) sensory neurons (Russell et al., 2002; Vincent et al., 2005; Singh et al., 2017; Oses et al., 2017). Furthermore, hyperglycemia has been shown to affect Schwann cell (SC) proliferation, migration and SC-neuron communication, which constitute crucial events during axonal regeneration (Gumy et al., 2008; Tosaki et al., 2008). Other studies have been based on dissociated DRG sensory neurons derived from adult diabetic animals, which offer the possibility of studying completely developed neurons. Studying neurons from adult animals is advantageous because they are not dependent on neurotrophins or serum for survival; so, they can be cultured in a defined medium of interest (Melli and Höke, 2009). To date, the vast majority of in vitro studies with adult primary neuronal cultures have been derived from diabetic animals treated with chemical agents that destroy pancreatic β-cells (such as streptozotocin or alloxan), which does not reliably represent the clinical signs of T2DM (reviewed by Sango et al., 2006). In addition, these experimental models present phenotypes that are usually milder and less comparable to human disease than what occurs with the BKS db/db mouse, probably the most robust model for DN described so far (Sullivan et al., 2007). Unlike T2DM, type-1 DM (T1DM)-associated DN progression is highly dependent on glucose control, suggesting that pathological mechanisms leading to DN progression in T2DM go beyond just hyperglycemia. Obesity and chronic hypertension, dyslipidemia, inflammation and insulin resistance are important contributors to DN in T2DM patients, thus, an acute in vitro or in vivo hyperglycemic state could not represent the mechanisms triggering axonal degeneration and cell apoptosis in this disease (Callaghan et al., 2012; De Gregorio et al., 2018). We propose that neuronal cultures derived from aged T2DM animals could represent, in a more accurate way, the environmental chronic damage suffered by a specific cell type or tissue.

To our knowledge, there are currently no well-characterized in vitro models to study neuronal function in advanced stages of DN derived from T2DM. Several studies have reported the culturing of adult DRG neurons in spontaneous T2DM adult mice; one of these studies used 8-week-old ob/ob mice to analyze the morphological response of neurons derived from diabetic animals to insulin (Grote et al., 2011); other studies have used DRG neurons derived from adult db/db mice to evaluate mitochondrial function and Ca+2 homeostasis in vitro (Kostyuk et al., 1999; Ma et al., 2014; Vincent et al., 2010). However, in these cases, neuronal cultures were not morphologically characterized in basal culture conditions; thus, it is not possible to determine the consequences of chronic exposition to a noxious environment over the neuritic regeneration capacity in these sensory neuron cultures in vitro.

In this study, we established an optimized protocol to cultivate DRG neurons derived from 6-month-old BKS db/db mice, a robust T2DM model that exhibits an advanced progression of DN at this age (De Gregorio et al., 2018). We used the ability of the DRG neuron to regenerate their neurites as an easy-to-analyze readout of neuronal function, and then we evaluated their capability to respond to commonly used neuritogenic molecules. Finally, as a proof of concept, we used this model to study a potential therapy for DN based on the mesenchymal stem cells (MSC) secretome, which has showed promising therapeutic effects in previous trials in embryonic DRG neurons subjected to hyperglycemia (Oses et al., 2017), and in an animal model of T2DM (De Gregorio et al., 2020).

RESULTS

Diabetic db/db mice as a model for T2DM

Previously, it has been shown that db/db mice develop obesity from 4 weeks of age, and hyperglycemia from 4 to 8 weeks of age (O'brien et al., 2014; Sullivan et al., 2007). In this study, we measured body weight and non-fasting glucose levels from week 14 until the animals were euthanized (week 26; Fig. S1). At 26 weeks of age, diabetic db/db animals displayed an increase of ∼twofold to ∼threefold in body weight and plasma glucose levels, respectively, compared to non-diabetic animals (Fig. S1). Previously, we showed that db/db mice also displayed increased levels of plasmatic triglyceride and glycated hemoglobin, and by week 26 they presented the main clinical signs of human DN, including a reduced nerve conduction velocity, a decreased intra-epidermal nerve fiber density and sensory loss in posterior limbs compared to non-diabetic littermates (De Gregorio et al., 2018). Thus, db/db mice represent a suitable T2DM model, resembling the main features of human disease.

DRG neurons obtained from aged diabetic mice survive and regenerate in the absence of serum and neurotrophins

Although most protocols and studies regarding DRG neurons have used embryonic, neonatal or juvenile (6-8 weeks old) rodents (Katzenell et al., 2017; Liu et al., 2013; Malin et al., 2007; Owen and Egerton, 2012; Sleigh et al., 2016), other research has shown evidence that DRG neurons obtained from aged rodents are able to survive and regenerate when they are cultured in vitro (Fukuda and Kameyama, 1979; Fukuda, 1985; Unsicker et al., 1985). However, there is little information about whether DRG neurons of aged (≥6-month-old) diabetic mice survive and regenerate when they are cultured in vitro in the absence of serum and neurotrophins. Here, we optimize a protocol for culturing lumbar DRG neurons obtained from aged (6-month-old) diabetic mice. After dissociation, DRG neuronal and non-neuronal cells were attached to poly-lysine substrate for 3 h in a FBS containing medium; after the attachment, FBS was withdrawn, and cells were maintained with N2 as the unique supplement and with cytosine arabinoside (AraC) to avoid non-neuronal cell proliferation. Then, the temporal course of neurite regeneration after 24, 48, and 72 h of in vitro culture was analyzed. Through bright-field microscopy, the regenerative potential for both diabetic and non-diabetic-derived neuron cultures was assessed. In Fig. S2, it is possible to differentiate neuronal cells from non-neuronal cells by their bright round morphology, which extends thin neurites to branch out over time until they form incipient neurite networks after 72 h of culture. Although a mitosis inhibitor was used (AraC), it is possible to identify some non-neuronal cells in both neuronal cultures. Previously, it has been described that the effect of anti-mitotic agents start occurring after 24 h, and the maximum effect is reached after 72 h in culture, suggesting that AraC supplementation is partially useful for short-term neuronal cultures (Liu et al., 2013).

Cultures of sensory neurons from diabetic mice displayed a reduced population of neurons and decreased neuritic regeneration

Previously, DN has been associated with the apoptosis of DRG neurons and with a decreased axonal regeneration in vivo (Sango et al., 2017; Schmeichel et al., 2003; Srinivasan et al., 2000). Furthermore, sensory neurons derived from T1DM-adult rodents also displayed neuritic regeneration defects when cultured in vitro (Sakaue et al., 2003; Zherebitskaya et al., 2009). Thus, we evaluated whether cultures of DRG cells obtained from T2DM mice displayed a reduced neuronal population and a decreased capacity to extend neurites in vitro, compared to DRG cells obtained from non-diabetic littermates. After 48 h in culture, cells were fixed and neurons were immunostained against β3-tubulin, and the total cell population was co-stained with the actin and nuclear markers Phalloidin and DAPI, respectively. Our results showed that cultures obtained from diabetic mice presented a reduced proportion of β3-positive cells (Fig. 1A,B); meanwhile, the total cell number was not significantly decreased (non-diabetic, 72±6 cells per field; diabetic: 66±7 cells per field; P=0.256, Student's t-test, n=4). Furthermore, DRG neurons from diabetic mice displayed a significant reduction in neuritogenic potential, defined as the percentage of neurons extending at least one neurite (more than 20 µm) (Fig. 1C).

Fig. 1.
Fig. 1.

Cultures of sensory neurons obtained from diabetic mice displayed a decreased population of neurons and neurite-bearing neurons. (A) Representative confocal images of DRG cultures obtained from diabetic and non-diabetic mice after 48 h of culturing, stained with the pan-neuronal marker β3-tubulin (green) and the actin stain Phalloidin (red). Scale bar: 50 µm. (B) Quantification of neuronal populations in the DRG cultures obtained from diabetic and non-diabetic mice, determined as the percentage of β3-positive cells. Total cell number was assessed by Phalloidin and DAPI staining (image not shown). (C) Quantification of neurite-bearing neurons in DRG cultures obtained from diabetic and non-diabetic mice, which was determined as the percentage of β3+ cells extending a neurite 20 µm or more. Data are mean±s.e.m. ***P<0.001, n=4 (unpaired two-tailed Student's t-test).

Next, we analyzed the potential of neuritic regeneration specifically in neurite-bearing neurons, to evaluate whether regenerating neurons from diabetic mice exhibited neurite outgrowth defects. For this, we fixed and immunostained neurons with the neuronal marker β3-tubulin, and cultures were analyzed by confocal microscopy. Fluorescence images were transformed to binary images and Sholl morphological analyses were performed, as described previously (Ferreira et al., 2014) (Fig. 2A,B). Our results demonstrated that DRG neurons obtained from diabetic mice exhibited a reduced neurite outgrowth and branching compared to neurons derived from non-diabetic littermates, which was quantified as the mean sum of intersections per neuron (Fig. 2B,C) and the mean maximum radius reached by a neuron (Fig. 2C,D), respectively. Both parameters were derived from Sholl analysis. Taken together, our results indicate that DRG cultures from aged db/db mice resemble some features of DRG neurons derived from diabetic mice in vivo.

Fig. 2.
Fig. 2.

Sensory neurons obtained from diabetic mice exhibited neurite outgrowth and neurite branching defects in vitro. (A) Representative binary images of DRG neurons obtained from diabetic and non-diabetic mice after 48 h of culturing, stained with the pan-neuronal marker β3-tubulin. (B) Sholl analysis of DRG neurons. (C-D) Quantification of the mean sum of intersections per neuron (C) and the mean maximum radius reached by neurons (D), as parameters derived from Sholl analysis. Data are mean±s.e.m. ***P<0.001, n=4 different cultures, 120 total neurons analyzed per experimental condition (unpaired two-tailed Student's t-test).

Cultures of sensory neurons from diabetic mice displayed a reduced response to neuritogenic factors

One of the main advantages of using in vitro DRG cultures is the possibility of evaluating the relative contribution of specific cell types to DN, by analyzing their molecular and functional responses in a controlled environment. To date, there is little knowledge regarding whether the decreased regeneration response associated with T2DM is determined by intrinsic neuronal defects, or by a deficient pro-regenerative microenvironment (e.g. dysfunctional SCs or reduced levels of neurotrophins). To address this issue, we analyzed the morphological response of DRG neurons from diabetic mice to two well-known neuritogenic molecules: the extracellular matrix protein laminin (herein referring to Laminin-1; also known as Laminin-111), and the nerve growth factor NGF.

We analyzed the morphological response of DRG neurons to laminin through a Sholl analysis (Fig. 3A,B). This analysis showed that sensory neurons from diabetic mice displayed an increased maximum radius and neurite branching compared to non-treated neurons from diabetic mice in response to laminin (Fig. 3C,D). However, this response was reduced compared to laminin-treated sensory neurons from non-diabetic mice. Similarly, sensory neurons from diabetic mice treated with NGF exhibited a significant increase in maximum radius and neurite branching compared to vehicle-treated neurons from diabetic mice Fig. 4A-D, but this treatment was not sufficient to match the morphology of NGF-treated neurons derived from non-diabetic mice. Taken together, these results suggest that neurons from diabetic mice maintain their ability to respond to external neuritogenic factors, but they may have intrinsic defects that prevent them from fully recovering the morphology of a healthy neuron.

Fig. 3.
Fig. 3.

Sensory neurons from diabetic mice displayed a reduced response to laminin in vitro. (A) Representative binary images of DRG neurons obtained from diabetic and non-diabetic mice pretreated with laminin, fixed after 48 h of culturing and stained with the pan-neuronal marker β3-tubulin. (B) Sholl analysis of DRG neurons shown in A. (C,D) Quantification of the mean sum of intersections per neuron (C) and the mean maximum radius reached by each neuron (D). Data are mean±s.e.m. Asterisks and hashtags indicate significant differences as determined by two-way ANOVA with post-hoc Tukey's test; hashtags indicate significant differences with non-treated neurons (n=4 different cultures, 120 total neurons analyzed per experimental condition). In C, left asterisk represents P=0.041; right asterisk, P=0.0001; left hashtag, P=0.0001; and right hashtag, P=0.0316. In D, left asterisk represents P=0.0254; right asterisk, P=0.0001; and hashtags, P=0.0001.

Fig. 4.
Fig. 4.

Sensory neurons from diabetic mice displayed a partial response to NGF in vitro. (A) Representative binary images of DRG neurons obtained from diabetic and non-diabetic mice treated with NGF or vehicle, fixed after 48 h of culturing and stained with the pan-neuronal marker β3-tubulin. (B) Sholl analysis of DRG neurons shown in A. (C-D) Quantification of the mean sum of intersections per neuron (C) and the mean maximum radius reached by each neuron (D). Data are mean±s.e.m. Asterisks and hashtags indicate significant differences by two-way ANOVA with post-hoc Tukey's test; hashtags indicate significant differences with non-treated neurons (n=4 different cultures, 120 total neurons analyzed per experimental condition). In C, left asterisk represents P=0.044; right asterisk, P=0.0001; left hashtag, P=0.0001; and right hashtag, P=0.0167. In D, left asterisk represents P=0.0206; right asterisk, P=0.0154; left hashtag, P=0.0004; and right hashtag, P=0.012.

Culture of sensory neurons from diabetic mice as an in vitro model for the evaluation of experimental therapies for DN

Finally, we used this model as a proof of concept, to study a promising experimental therapy based on the use of the MSC secretome, which we previously evaluated in the culture of hyperglycemia-treated embryonic DRG neurons (Oses et al., 2017) and in diabetic db/db mice in vivo (De Gregorio et al., 2020). We cultured adipose tissue-derived MSCs, as described previously (Oses et al., 2017), to obtain concentrated fractions of their secretome. Next, we treated DRG neurons from diabetic and non-diabetic mice with the MSC secretome in vitro and carried out a morphological assessment by confocal microscopy. Sholl analysis results (Fig. 5A,B) indicated that MSC secretome-treated neurons from diabetic mice displayed a slight but significant increase in maximum radius and Sholl intersections compared to vehicle-treated neurons from diabetic mice (Fig. 5C,D), suggesting that proliferative and neurotrophic molecules present in the secretome may act directly over neurons. This result indicates that cultures of DRG neurons derived from diabetic mice constitute a suitable model to study DN mechanisms, or to assay new therapies aiming to avoid neuropathy progression.

Fig. 5.
Fig. 5.

MSC secretome treatment partially restored neurite growth and neurite branching in sensory neurons from diabetic mice. (A) Representative binary images of DRG neurons obtained from diabetic and non-diabetic mice treated with MSC secretome or vehicle, fixed after 48 h of culturing and stained with the pan-neuronal marker β3-tubulin. (B) Sholl analysis of DRG neurons shown in A. (C-D) Quantification of the mean sum of intersections per neuron (C) and the mean maximum radius reached by each neuron (D). Data are mean±s.e.m. Asterisks indicate significant differences by one-way ANOVA with post-hoc Tukey's test (n=4 different cultures, 120 total neurons analyzed per experimental condition). In C, upper asterisk represents P=0.0249; middle asterisk, P=0.0001; and lower asterisk, P=0.0249; In D, upper asterisk represents P=0.0006; middle asterisk, P=0.0001; and lower asterisk, P=0.019.

DISCUSSION

Although in vivo models of diabetes provide a physiological context highly valuable for studying DN, this system complexity has important limitations for dissecting the molecular events triggering nerve dysfunction. Thus, in vitro cultures have emerged as useful simplified models that complement studies carried out on whole animals. As this model allows the study of neurons in an autonomous manner, it could also be useful for complementary studies carried out in vivo, to demonstrate that experimental treatments that reduce the progression of DN could act directly over the neuronal cells. However, currently characterized models used for DN research are limiting, as they do not recreate the chronic and systemic damage suffered by peripheral neurons and nerves typically observed in T2DM.

In this study, we characterized the culture of DRG neurons obtained from 6-month-old diabetic animals using a morphological analysis as an easy-to-analyze readout of neuronal function. The main advantage of this model is that neurons have a chronic exposure to a harmful environment that goes beyond hyperglycemia, and that includes nerve inflammation, increased oxidative stress, dyslipidemia, insulin resistance and hypertension (Burke et al., 2017; Campero et al., 2015; De Gregorio et al., 2018). In fact, we demonstrated that sensory neurons of diabetic animals cultured in basal conditions exhibited morphological defects compared to neurons from non-diabetic mice, which could allow the analysis of other neuronal functions without adding additional toxic factors to the culture plate.

One limitation of DRG cultures is that neuronal isolation requires axotomy of both central and peripheral nerves, which activates a potent transcriptional network associated with axonal regeneration (He and Jin, 2016), and needs to be considered when studying associated signaling pathways. A second limitation is that DRG cultures include non-neuronal contaminating cells, such as fibroblasts, satellite glia, and SCs. Although it is possible to obtain highly pure DRG cultures by using mitosis blocking agents, this strategy has only been effective in long-term cultures (Hattangady and Rajadhyaksha, 2009; Liu et al., 2013).

To date, there is ample evidence that axonal regeneration is impaired in diabetes in vivo, but its precise mechanisms have not been completely elucidated. Among the proposed mechanisms are SC dysfunction, alteration and glycation of extracellular matrix components, reduced expression of neurotrophic factors and enhanced activity of growth-inhibitory molecules (Sango et al., 2017). Axonal regeneration is also impaired in neurons derived from diabetic animals in culture, in which molecules such as metalloproteinases (MMP-2; Ali et al., 2014), neurotrophins (neuritin; Karamoysoyli et al., 2008) and phosphatases (PTEN; Singh et al., 2014) have been implicated, but the molecular mechanisms are still poorly understood. Furthermore, the contribution of specific cell types to the causality and progression of neuropathies remains unexplored. Previous studies have shown that neurons from diabetic animals exhibited reduced levels of NGF, insulin and insulin-like signaling (Aghanoori et al., 2019; Lu et al., 2020; Peeraer et al., 2011; Tosaki et al., 2008). However, it is not clear whether these defects resulted from low levels of trophic support (e.g. by a reduced SC population or by low levels of neurotrophins secretion), or a reduced ability of neurons to respond to stimuli. Our results demonstrated that neurons from diabetic mice displayed a significant response to NFG, but it was reduced compared to neurons from non-diabetic mice treated with NGF. Previously, neurons from diabetic animals were shown to have a poor growth cone response to NGF, which could suggest signaling defects in response to this growth factor (Lu et al., 2020). On the other hand, basement membranes (BMs) play a key role in nervous system development and in maintaining neuronal function in adulthood (Yurchenco, 2011). Laminins, a major component of BMs, are enriched in peripheral nerves after injury and have been proposed as a potent stimulator of nerve regeneration (David et al., 1995; Gonzalez-Perez et al., 2013; Nieuwenhuis et al., 2018). Various studies have demonstrated that DN induces changes in BM composition, leading to an increase in the thickness and rigidity (Hill, 2009; King et al., 1989; Kundalić et al., 2014; To et al., 2013); however, these structural changes have been poorly explored. Although laminin level seems to be similar between nerves from healthy and diabetic patients (Hill, 2009; To et al., 2013), several studies indicated that neurons from diabetic animals displayed a reduced response to laminin, with an effect of reduced adhesion to extracellular matrix proteins and a decreased laminin quality triggered by excessive glycation (Duran-Jimenez et al., 2009; Federoff et al., 1993; King, 2001; Sango et al., 1995). Here, we demonstrated that DRG neurons from diabetic mice exhibited a reduced regenerative response to laminin, and this response was intrinsic to neurons as the laminin coating was the same in both conditions. Thus, it is possible that regenerative defects associated with neurons of diabetic mice in vivo could be determined by both intrinsic defects (e.g. by a reduced adhesion or signaling defects) and poor quality or decreased levels of pro-regenerative extracellular matrix proteins and neurotrophins.

Finally, we used this in vitro model to evaluate the efficiency of a new therapy based on the MSC secretome. In a previous study, we showed that the systemic administration of the MSC secretome to db/db mice was able to completely reverse the main structural and functional defects associated with DN (De Gregorio et al., 2020); however, it was not possible to evaluate whether the MSC secretome acts directly over neurons (in a cell-autonomous manner), or acts indirectly by improving the neuronal microenvironment. Here, we demonstrated that the MSC secretome partially reverts the impaired regeneration of sensorial neurons from diabetic animals, suggesting that the MSC-derived secretome could act directly over neurons, and indirectly ameliorating the noxious nerve microenvironment. As the MSC secretome is composed of hundreds of different molecules, it may be difficult to identify those that are responsible for the neuritogenic activity. We previously carried out a proteomic analysis of the MSC secretome and detected the neuron-derived neurotrophic factor (NDNF) as one of the most abundant proteins (De Gregorio et al., 2020). NDNF has been previously described as a neurotrophic factor that induces neuritic outgrowth and exerts neuroprotection against harmful stimuli in mouse hippocampal neurons in vitro (Kuang et al., 2010). Thus, it remains to be determined whether this molecule is the main molecule responsible for the neuritogenic effect of the MSC secretome. Previously, it was shown that brain-derived neurotrophic factor (BDNF) mediated axonal outgrowth in cortical and hippocampal neurons treated with MSC secretome in vitro (Martins et al., 2017). Thus, the neuritogenic effect could be due to a set of molecules rather than a single one.

The currently characterized in vitro model could also be extrapolated for studying other parameters of interest associated with T2DM, such as cell survival, synaptic structure formation and activity, electrophysiological responses, interactions with glial cells, etc., in a controlled environment, either under standard or experimental conditions of interest.

MATERIALS AND METHODS

Animals

Transgenic mice (BKS.Cg-m+/+Leprdb/J) that spontaneously develop T2DM were purchased from The Jackson Laboratory. Female diabetic (db/db) and non-diabetic (db/+) mice were housed at constant temperature and humidity, with a 12-h light/dark cycle and unrestricted access to standard chow and water. All animal protocols were approved by the Animal Ethics Committee of Universidad del Desarrollo. Six-month-old mice were euthanized by an overdose of anesthesia, and L3-L5 ganglia were dissected and used for culture preparation (additional ganglia or all the ganglia may be used, according to work objectives).

Measurement of blood glucose

Non-fasting blood glucose levels were measured using a glucometer (Accu-Chek Performa System, Roche). Blood samples were obtained from the tail of alert animals every 2 weeks (from week 14 to week 26). Mice with a sustained glycemia value of over 250 mg/dl were considered diabetic.

Isolation and culturing of adipose-derived MSCs

Human adipose-derived MSCs were isolated from fresh subcutaneous adipose tissue samples (abdominal region) obtained from liposuction aspirates of four healthy female human donors undergoing cosmetic liposuction at Clínica Alemana, Chile, as described previously (Oses et al., 2017). Written informed consent was obtained for all samples, and the protocols used were approved by the Ethics Committee of Universidad del Desarrollo and were carried out according to the ethical principles outlined in the Declaration of Helsinki. MSC culture and cell characterization have been described previously (Oses et al., 2017). Briefly, when cells reached 70% confluency, plates were rinsed three times with PBS and cells were incubated for 48 h in α-minimum essential medium without fetal bovine serum (FBS). The media were centrifuged at 400 g for 10 min to remove whole cells, and the supernatants were centrifuged again at 5000 g for 20 min to remove cell debris. Finally, conditioned media were filtered in 0.22-µm filters, concentrated 10× (v/v) using 3 kDa cut-off filters (Millipore) and stored at −80°C until use.

Primary cultures of DRG neurons

DRGs from L3-L5 were dissected from 26-week-old animals, and enzymatically digested by incubation for 25 min at 37°C with 0.6% trypsin (Gibco), and then for 25 min at 37°C with 0.5% collagenase type I (Gibco). The enzymatic activity was halted by adding 1 ml of FBS, and tissue suspension was centrifuged at 400 g for 5 min. Then, the pellet was resuspended in Dulbecco's modified Eagle's medium (DMEM)/F12 (Gibco) with 10% FBS and mechanically dissociated. A total of 5000 cells were plated on coverslips coated with 0.05% poly-D-lysine (Sigma-Aldrich) or Poly-D-lysine plus laminin (1 µg/µl, Sigma-Aldrich). Neurons were allowed to attach to the substratum for 4 h before changing medium to DMEM/F12 containing N2 supplement (Gibco) and AraC (Sigma-Aldrich). Where indicated, NGF (10 ng/ml, Alomone Labs), MSC secretome (containing 5 µg/ml of protein) or vehicle (PBS) were added to the culture medium and replaced after 24 h of treatment. After 44 h in culture (48 h in total), cells were fixed with 4% paraformaldehyde containing 4% sucrose for 20 min, and neurons were immunostained with β3-tubuline antibody (TU-20, 1:150, Santa Cruz Biotechnology). Phalloidin (Santa Cruz Biotechnology, sc-363794, 1:500) and DAPI (1:500, AppliChem) were used to stain the actin cytoskeleton and nuclei, respectively, of neuronal and non-neuronal cells. Samples were analyzed by confocal microscopy (Fluoview FV10i; Olympus). All the experiments were carried out with four different cultures per condition.

Sholl analysis

Sholl analysis was carried out as described previously (Ferreira et al., 2014). Briefly, confocal images were transformed to 8-bit binary images, and then were quantified with the Sholl analysis tool (Fiji software; National Institutes of Health). The distance/neurite-number profile, the maximum radius reached by each neuron, and the sum of intersections for each neuron were evaluated. To facilitate the analysis of neuronal morphology, we randomly selected isolated neurons. To avoid quantifying dying neurons, we analyzed only neurons extending at least one neurite 20 µm or more. Samples from four animals per experimental group were evaluated (30 neurons per experiment, 120 neurons in total).

Statistical analysis

Quantitative data were presented as mean±s.e.m. Comparisons between two different conditions were analyzed using an unpaired two-tailed Student's t-test. Comparisons between groups were performed using one-way ANOVA or two-way ANOVA with Tukey's post-test. Grouped repeated measures were analyzed with two-way ANOVA with Bonferroni post-test. P<0.05 was considered statistically significant.

Acknowledgements

The authors thank Dr Anne Bliss for English editing of the manuscript.

Footnotes

  • Competing interests

    The authors declare no competing or financial interests.

  • Author contributions

    Conceptualization: C.D.G., F.E.; Methodology: C.D.G., F.E.; Formal analysis: C.D.G.; Investigation: C.D.G.; Writing - original draft: C.D.G.; Writing - review & editing: F.E.; Supervision: F.E.; Project administration: F.E.; Funding acquisition: F.E.

  • Funding

    This work was supported by the Fondo Nacional de Desarrollo Científico y Tecnológico (1170712).

  • Supplementary information

    Supplementary information available online at https://dmm.biologists.org/lookup/doi/10.1242/dmm.046334.supplemental

  • Received June 25, 2020.
  • Accepted November 17, 2020.
http://creativecommons.org/licenses/by/4.0

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution and reproduction in any medium provided that the original work is properly attributed.

References

  1. ↵
    1. Aghanoori, M.-R.,
    2. Smith, D. R.,
    3. Shariati-Ievari, S.,
    4. Ajisebutu, A.,
    5. Nguyen, A.,
    6. Desmond, F.,
    7. Jesus, C. H. A.,
    8. Zhou, X.,
    9. Calcutt, N. A.,
    10. Aliani, M. et al.
    (2019). Insulin-like growth factor-1 activates AMPK to augment mitochondrial function and correct neuronal metabolism in sensory neurons in type 1 diabetes. Mol. Metab. 20, 149-165. doi:10.1016/j.molmet.2018.11.008
    OpenUrlCrossRef
  2. ↵
    1. Ali, S.,
    2. Driscoll, H. E.,
    3. Newton, V. L. and
    4. Gardiner, N. J.
    (2014). Matrix metalloproteinase-2 is downregulated in sciatic nerve by streptozotocin induced diabetes and/or treatment with minocycline: Implications for nerve regeneration. Exp. Neurol. 261, 654-665. doi:10.1016/j.expneurol.2014.08.017
    OpenUrlCrossRefPubMed
  3. ↵
    1. Argoff, C. E.,
    2. Cole, B. E.,
    3. Fishbain, D. A. and
    4. Irving, G. A.
    (2006). Diabetic peripheral neuropathic pain: Clinical and quality-of-life issues. Mayo Clin. Proc. 81, S3. doi:10.1016/S0025-6196(11)61474-2
    OpenUrlCrossRefPubMed
  4. ↵
    1. Boulton, A. J. M.,
    2. Vinik, A. I.,
    3. Arezzo, J. C.,
    4. Bril, V.,
    5. Feldman, E. L.,
    6. Freeman, R.,
    7. Malik, R. A.,
    8. Maser, R. E.,
    9. Sosenko, J. M. and
    10. Ziegler, D.
    (2005). Diabetic Neuropathies. Diabetes Care 28, 956-962. doi:10.2337/diacare.28.4.956
    OpenUrlFREE Full Text
  5. ↵
    1. Burke, S. J.,
    2. Batdorf, H. M.,
    3. Burk, D. H.,
    4. Noland, R. C.,
    5. Eder, A. E.,
    6. Boulos, M. S.,
    7. Karlstad, M. D. and
    8. Collier, J. J.
    (2017). db/db mice exhibit features of human type 2 diabetes that are not present in weight-matched C57BL/6J mice fed a western diet. J. Diabetes Res. 2017, 8503754. doi:10.1155/2017/8503754
    OpenUrlCrossRef
  6. ↵
    1. Callaghan, B. C.,
    2. Hur, J. and
    3. Feldman, E. L.
    (2012). Diabetic neuropathy: one disease or two? Curr. Opin. Neurol. 25, 536-541. doi:10.1097/WCO.0b013e328357a797
    OpenUrlCrossRefPubMed
  7. ↵
    1. Campero, M.,
    2. Ezquer, M. and
    3. Ezquer, F.
    (2015). Nerve excitability and structural changes in myelinated axons from diabetic mice. Exp. Clin. Endocrinol. Diabetes 123, 485-491. doi:10.1055/s-0035-1559606
    OpenUrlCrossRef
  8. ↵
    1. David, S.,
    2. Braun, P. E.,
    3. Jackson, D. L.,
    4. Kottis, V. and
    5. McKerracher, L.
    (1995). Laminin overrides the inhibitory effects of peripheral nervous system and central nervous system myelin-derived inhibitors of neurite growth. J. Neurosci. Res. 42, 594-602. doi:10.1002/jnr.490420417
    OpenUrlCrossRefPubMedWeb of Science
  9. ↵
    1. De Gregorio, C.,
    2. Contador, D.,
    3. Campero, M.,
    4. Ezquer, M. and
    5. Ezquer, F.
    (2018). Characterization of diabetic neuropathy progression in a mouse model of type 2 diabetes mellitus. Biol. Open 7, bio036830. doi:10.1242/bio.036830
    OpenUrlAbstract/FREE Full Text
  10. ↵
    1. De Gregorio, C.,
    2. Contador, D.,
    3. Díaz, D.,
    4. Cárcamo, C.,
    5. Santapau, D.,
    6. Lobos-Gonzalez, L.,
    7. Acosta, C.,
    8. Campero, M.,
    9. Carpio, D.,
    10. Gabriele, C. et al.
    (2020). Human adipose-derived mesenchymal stem cell-conditioned medium ameliorates polyneuropathy and foot ulceration in diabetic BKS db/db mice. Stem Cell Res. Ther. 11, 168. doi:10.1186/s13287-020-01680-0
    OpenUrlCrossRef
  11. ↵
    1. Duran-Jimenez, B.,
    2. Dobler, D.,
    3. Moffatt, S.,
    4. Rabbani, N.,
    5. Streuli, C. H.,
    6. Thornalley, P. J.,
    7. Tomlinson, D. R. and
    8. Gardiner, N. J.
    (2009). Advanced glycation end products in extracellular matrix proteins contribute to the failure of sensory nerve regeneration in diabetes. Diabetes 58, 2893-2903. doi:10.2337/db09-0320
    OpenUrlAbstract/FREE Full Text
  12. ↵
    1. Federoff, H. J.,
    2. Lawrence, D. and
    3. Brownlee, M.
    (1993). Nonenzymatic glycosylation of laminin and the laminin peptide CIKVAVS inhibits neurite outgrowth. Diabetes 42, 509-513. doi:10.2337/diab.42.4.509
    OpenUrlAbstract/FREE Full Text
  13. ↵
    1. Feldman, E. L.,
    2. Callaghan, B. C.,
    3. Pop-Busui, R.,
    4. Zochodne, D. W.,
    5. Wright, D. E.,
    6. Bennett, D. L.,
    7. Bril, V.,
    8. Russell, J. W. and
    9. Viswanathan, V.
    (2019). Diabetic neuropathy. Nat. Rev. Dis. Prim. 5, 41. doi:10.1038/s41572-019-0092-1
    OpenUrlCrossRefPubMed
  14. ↵
    1. Ferreira, T. A.,
    2. Blackman, A. V.,
    3. Oyrer, J.,
    4. Jayabal, S.,
    5. Chung, A. J.,
    6. Watt, A. J.,
    7. Sjöström, P. J. and
    8. van Meyel, D. J.
    (2014). Neuronal morphometry directly from bitmap images. Nat. Methods 11, 982-984. doi:10.1038/nmeth.3125
    OpenUrlCrossRefPubMed
  15. ↵
    1. Forbes, J. M. and
    2. Cooper, M. E.
    (2013). Mechanisms of diabetic complications. Physiol. Rev. 93, 137-188. doi:10.1152/physrev.00045.2011
    OpenUrlCrossRefPubMed
  16. ↵
    1. Fukuda, J.
    (1985). Nerve cells of adult and aged mice grown in a monolayer culture: age-associated changes in morphological and physiological properties of dorsal root ganglion cells in vitro. Dev. Neurosci. 7, 374-394. doi:10.1159/000112304
    OpenUrlCrossRefPubMed
  17. ↵
    1. Fukuda, J. U. N. and
    2. Kameyama, M.
    (1979). Enhancement of Ca spikes in nerve cells of adult mammals during neurite growth in tissue culture. Nature 279, 546-548. doi:10.1038/279546a0
    OpenUrlCrossRefPubMed
  18. ↵
    1. Gonzalez-Perez, F.,
    2. Udina, E. and
    3. Navarro, X.
    (2013). Extracellular matrix components in peripheral nerve regeneration. Int. Rev. Neurobiol. 108, 257-275. doi:10.1016/B978-0-12-410499-0.00010-1
    OpenUrlCrossRefPubMed
  19. ↵
    1. Grote, C. W.,
    2. Morris, J. K.,
    3. Ryals, J. M.,
    4. Geiger, P. C. and
    5. Wright, D. E.
    (2011). Insulin receptor substrate 2 expression and involvement in neuronal insulin resistance in diabetic neuropathy. Exp. Diabetes Res. 2011, 212571. doi:10.1155/2011/212571
    OpenUrlCrossRefPubMed
  20. ↵
    1. Gumy, L. F.,
    2. Bampton, E. T. W. and
    3. Tolkovsky, A. M.
    (2008). Hyperglycaemia inhibits Schwann cell proliferation and migration and restricts regeneration of axons and Schwann cells from adult murine DRG. Mol. Cell. Neurosci. 37, 298-311. doi:10.1016/j.mcn.2007.10.004
    OpenUrlCrossRefPubMed
  21. ↵
    1. Hattangady, N. G. and
    2. Rajadhyaksha, M. S.
    (2009). A brief review of in vitro models of diabetic neuropathy. Int. J. Diabetes Dev. Ctries. 29, 143-149. doi:10.4103/0973-3930.57344
    OpenUrlCrossRefPubMed
  22. ↵
    1. He, Z. and
    2. Jin, Y.
    (2016). Intrinsic Control of Axon Regeneration. Neuron 90, 437-451. doi:10.1016/j.neuron.2016.04.022
    OpenUrlCrossRefPubMed
  23. ↵
    1. Hill, R.
    (2009). Extracellular matrix remodelling in human diabetic neuropathy. J. Anat. 214, 219-225. doi:10.1111/j.1469-7580.2008.01026.x
    OpenUrlCrossRefPubMed
  24. ↵
    International Diabetes Federation. (2019). IDF Diabetes Atlas, 9th edn. Brussels, Belgium: International Diabetes Federation.
  25. ↵
    1. Karamoysoyli, E.,
    2. Burnand, R. C.,
    3. Tomlinson, D. R. and
    4. Gardiner, N. J.
    (2008). Neuritin mediates nerve growth factor–induced axonal regeneration and is deficient in experimental diabetic neuropathy. Diabetes 57, 181-189. doi:10.2337/db07-0895
    OpenUrlAbstract/FREE Full Text
  26. ↵
    1. Katzenell, S.,
    2. Cabrera, J. R.,
    3. North, B. J. and
    4. Leib, D. A.
    (2017). Isolation, purification, and culture of primary murine sensory neurons. Methods Mol. Biol. 1656, 229-251. doi:10.1007/978-1-4939-7237-1_15
    OpenUrlCrossRef
  27. ↵
    1. King, R. H.
    (2001). The role of glycation in the pathogenesis of diabetic polyneuropathy. Mol. Pathol. 54, 400-408.
    OpenUrlAbstract/FREE Full Text
  28. ↵
    1. King, R. H. M.,
    2. Llewelyn, J. G.,
    3. Thomas, P. K.,
    4. Gilbey, S. G. and
    5. Watkins, P. J.
    (1989). Diabetic neuropathy: abnormalities of Schwann cell and perineurial basal laminae. Implications for diabetic vasculopathy. Neuropathol. Appl. Neurobiol. 15, 339-355. doi:10.1111/j.1365-2990.1989.tb01234.x
    OpenUrlCrossRefPubMedWeb of Science
  29. ↵
    1. Kostyuk, E.,
    2. Svichar, N.,
    3. Shishkin, V. and
    4. Kostyuk, P.
    (1999). Role of mitochondrial dysfunction in calcium signalling alterations in dorsal root ganglion neurons of mice with experimentally-induced diabetes. Neuroscience 90, 535-541. doi:10.1016/S0306-4522(98)00471-0
    OpenUrlCrossRefPubMedWeb of Science
  30. ↵
    1. Kuang, X.-L.,
    2. Zhao, X.-M.,
    3. Xu, H.-F.,
    4. Shi, Y.-Y.,
    5. Deng, J.-B. and
    6. Sun, G.-T.
    (2010). Spatio-temporal expression of a novel neuron-derived neurotrophic factor (NDNF) in mouse brains during development. BMC Neurosci.. 11, 137. doi:10.1186/1471-2202-11-137
    OpenUrlCrossRefPubMed
  31. ↵
    1. Kundalić, B.,
    2. Ugrenović, S.,
    3. Jovanović, I.,
    4. Stefanović, N.,
    5. Petrović, V.,
    6. Kundalić, J.,
    7. Stojanović, V.,
    8. Živković, V. and
    9. Antić, V.
    (2014). Morphometric analysis of connective tissue sheaths of sural nerve in diabetic and nondiabetic patients. Biomed Res. Int. 2014, 870930. doi:10.1155/2014/870930
    OpenUrlCrossRef
  32. ↵
    1. Liu, R.,
    2. Lin, G. and
    3. Xu, H.
    (2013). An efficient method for dorsal root ganglia neurons purification with a one-time anti-mitotic reagent treatment. PLoS ONE 8, 3-9. doi:10.1371/journal.pone.0060558
    OpenUrlCrossRef
  33. ↵
    1. Lu, M.,
    2. Yi, T.,
    3. Xiong, Y.,
    4. Wang, Q. and
    5. Yin, N.
    (2020). Cortex Mori Radicis extract promotes neurite outgrowth in diabetic rats by activating PI3K/AKT signaling and inhibiting Ca2+ influx associated with upregulation of transient receptor potential canonical channel 1. Mol. Med. Rep. 21, 320-328. doi:10.3892/mmr.2020.11008
    OpenUrlCrossRef
  34. ↵
    1. Ma, J.,
    2. Farmer, K. L.,
    3. Pan, P.,
    4. Urban, M. J.,
    5. Zhao, H.,
    6. Blagg, B. S. J. and
    7. Dobrowsky, R. T.
    (2014). Heat shock protein 70 is necessary to improve mitochondrial bioenergetics and reverse diabetic sensory neuropathy following KU-32 therapy. J. Pharmacol. Exp. Ther. 348, 281-292. doi:10.1124/jpet.113.210435
    OpenUrlAbstract/FREE Full Text
  35. ↵
    1. Malin, S. A.,
    2. Davis, B. M. and
    3. Molliver, D. C.
    (2007). Production of dissociated sensory neuron cultures and considerations for their use in studying neuronal function and plasticity. Nat. Protoc. 2, 152-160. doi:10.1038/nprot.2006.461
    OpenUrlCrossRefPubMedWeb of Science
  36. ↵
    1. Martins, L. F.,
    2. Costa, R. O.,
    3. Pedro, J. R.,
    4. Aguiar, P.,
    5. Serra, S. C.,
    6. Teixeira, F. G.,
    7. Sousa, N.,
    8. Salgado, A. J. and
    9. Almeida, R. D.
    (2017). Mesenchymal stem cells secretome-induced axonal outgrowth is mediated by BDNF. Sci. Rep. 7, 4153. doi:10.1038/s41598-017-03592-1
    OpenUrlCrossRef
  37. ↵
    1. Melli, G. and
    2. Höke, A.
    (2009). Dorsal root ganglia sensory neuronal cultures: a tool for drug discovery for peripheral neuropathies. Expert Opin. Drug Discov. 4, 1035-1045. doi:10.1517/17460440903266829
    OpenUrlCrossRefPubMedWeb of Science
  38. ↵
    1. Muller, K. A.,
    2. Ryals, J. M.,
    3. Feldman, E. L. and
    4. Wright, D. E.
    (2008). Abnormal muscle spindle innervation and large-fiber neuropathy in diabetic mice. Diabetes 57, 1693-1701. doi:10.2337/db08-0022
    OpenUrlAbstract/FREE Full Text
  39. ↵
    1. Nieuwenhuis, B.,
    2. Haenzi, B.,
    3. Andrews, M. R.,
    4. Verhaagen, J. and
    5. Fawcett, J. W.
    (2018). Integrins promote axonal regeneration after injury of the nervous system. Biol. Rev. Camb. Philos. Soc. 93, 1339-1362. doi:10.1111/brv.12398
    OpenUrlCrossRefPubMed
  40. ↵
    1. O'brien, P. D.,
    2. Sakowski, S. A. and
    3. Feldman, E. L.
    (2014). Mouse models of diabetic neuropathy. ILAR J. 54, 259-272. doi:10.1093/ilar/ilt052
    OpenUrlCrossRefPubMed
  41. ↵
    1. Oses, C.,
    2. Olivares, B.,
    3. Ezquer, M.,
    4. Acosta, C.,
    5. Bosch, P.,
    6. Donoso, M.,
    7. Léniz, P. and
    8. Ezquer, F.
    (2017). Preconditioning of adipose tissue-derived mesenchymal stem cells with deferoxamine increases the production of pro-angiogenic, neuroprotective and anti-inflammatory factors: Potential application in the treatment of diabetic neuropathy. PLoS ONE 12, e0178011. doi:10.1371/journal.pone.0178011
    OpenUrlCrossRef
  42. ↵
    1. Owen, D. E. and
    2. Egerton, J.
    (2012). Culture of dissociated sensory neurons from dorsal root ganglia of postnatal and adult rats. Methods Mol. Biol. 846, 179-187. doi:10.1007/978-1-61779-536-7_16
    OpenUrlCrossRefPubMed
  43. ↵
    1. Peeraer, E.,
    2. van Lutsenborg, A.,
    3. Verheyen, A.,
    4. de Jongh, R.,
    5. Nuydens, R. and
    6. Meert, T. F.
    (2011). Pharmacological evaluation of rat dorsal root ganglion neurons as an in vitro model for diabetic neuropathy. J. Pain Res. 4, 55-65. doi:10.2147/JPR.S15452
    OpenUrlCrossRefPubMed
  44. ↵
    1. Pittenger, G. and
    2. Vinik, A.
    (2003). Nerve growth factor and diabetic neuropathy. Exp. Diabesity Res. 4, 271-285. doi:10.1155/EDR.2003.271
    OpenUrlCrossRefPubMed
  45. ↵
    1. Reuter, T. Y.
    (2007). Diet-induced models for obesity and type 2 diabetes. Drug Discov. Today Dis. Model. 4, 3-8. doi:10.1016/j.ddmod.2007.09.004
    OpenUrlCrossRef
  46. ↵
    1. Russell, J. W.,
    2. Golovoy, D.,
    3. Vincent, A. M.,
    4. Mahendru, P. I. A.,
    5. Olzmann, J. A.,
    6. Mentzer, A. and
    7. Feldman, E. V. A. L.
    (2002). High glucose-induced oxidative stress and mitochondrial dysfunction in neurons. FASEB J. 16, 1738-1748. doi:10.1096/fj.01-1027com
    OpenUrlCrossRefPubMedWeb of Science
  47. ↵
    1. Sakaue, Y.,
    2. Sanada, M.,
    3. Sasaki, T.,
    4. Kashiwagi, A. and
    5. Yasuda, H.
    (2003). Amelioration of retarded neurite outgrowth of dorsal root ganglion neurons by overexpression of PKCδ in diabetic rats. Neuroreport 14, 431-436. doi:10.1097/00001756-200303030-00027
    OpenUrlCrossRefPubMed
  48. ↵
    1. Sango, K.,
    2. Home, H.,
    3. Okamura, A.,
    4. Inouet, S. and
    5. Takenaka, T.
    (1995). Diabetes impairs DRG neuronal attachment to extracellular matrix proteins in vitro. Brain Res. Bull. 37, 533-537. doi:10.1016/0361-9230(95)00057-L
    OpenUrlCrossRefPubMedWeb of Science
  49. ↵
    1. Sango, K.,
    2. Saito, H.,
    3. Takano, M.,
    4. Tokashiki, A.,
    5. Inoue, S. and
    6. Horie, H.
    (2006). Cultured adult animal neurons and schwann cells give us new insights into diabetic neuropathy. Curr. Diabetes Rev. 2, 169-183. doi:10.2174/157339906776818613
    OpenUrlCrossRefPubMed
  50. ↵
    1. Sango, K.,
    2. Mizukami, H.,
    3. Horie, H. and
    4. Yagihashi, S.
    (2017). Impaired axonal regeneration in diabetes. perspective on the underlying mechanism from in vivo and in vitro experimental studies. Front. Endocrinol. (Lausanne). 8, 12. doi:10.3389/fendo.2017.00012
    OpenUrlCrossRef
  51. ↵
    1. Schmeichel, A. M.,
    2. Schmelzer, J. D. and
    3. Low, P. A.
    (2003). Oxidative injury and apoptosis of dorsal root ganglion neurons in chronic experimental diabetic neuropathy. Diabetes 52, 165-171. doi:10.2337/diabetes.52.1.165
    OpenUrlAbstract/FREE Full Text
  52. ↵
    1. Schratzberger, P.,
    2. Walter, D. H.,
    3. Rittig, K.,
    4. Bahlmann, F. H.,
    5. Pola, R.,
    6. Curry, C.,
    7. Silver, M.,
    8. Krainin, J. G.,
    9. Weinberg, D. H.,
    10. Ropper, A. H. et al.
    (2001). Reversal of experimental diabetic neuropathy by VEGF gene transfer. J. Clin. Invest. 107, 1083-1092. doi:10.1172/JCI12188
    OpenUrlCrossRefPubMedWeb of Science
  53. ↵
    1. Shi, X.,
    2. Chen, Y.,
    3. Nadeem, L. and
    4. Xu, G.
    (2013a). Beneficial effect of TNF-α inhibition on diabetic peripheral neuropathy. J. Neuroinflammation 10, 836. doi:10.1186/1742-2094-10-69
    OpenUrlCrossRef
  54. ↵
    1. Shi, T.-J. S.,
    2. Zhang, M.-D.,
    3. Zeberg, H.,
    4. Nilsson, J.,
    5. Grünler, J.,
    6. Liu, S.-X.,
    7. Xiang, Q.,
    8. Persson, J.,
    9. Fried, K. J.,
    10. Catrina, S. B. et al.
    (2013b). Coenzyme Q10 prevents peripheral neuropathy and attenuates neuron loss in the db-/db- mouse, a type 2 diabetes model. Proc. Natl. Acad. Sci. USA 110, 690-695. doi:10.1073/pnas.1220794110
    OpenUrlAbstract/FREE Full Text
  55. ↵
    1. Singh, B.,
    2. Singh, V.,
    3. Krishnan, A.,
    4. Koshy, K.,
    5. Martinez, J. A.,
    6. Cheng, C.,
    7. Almquist, C. and
    8. Zochodne, D. W.
    (2014). Regeneration of diabetic axons is enhanced by selective knockdown of the PTEN gene. Brain 137, 1051-1067. doi:10.1093/brain/awu031
    OpenUrlCrossRefPubMed
  56. ↵
    1. Singh, J. N.,
    2. Negi, G.,
    3. Kharatmal, S. B.,
    4. Mule, N. K.,
    5. Sharma, D. and
    6. Sharma, S. S.
    (2017). Short-term extracellular glucose exposure alters neurite outgrowth and intracellular reactive oxygen species without altering viability in neuronal cells. Indian J. Exp. Biol. 55, 648-654.
    OpenUrl
  57. ↵
    1. Sleigh, J. N.,
    2. Weir, G. A. and
    3. Schiavo, G.
    (2016). A simple, step-by-step dissection protocol for the rapid isolation of mouse dorsal root ganglia. BMC Res. Notes 9, 4-10. doi:10.1186/s13104-016-1915-8
    OpenUrlCrossRef
  58. ↵
    1. Srinivasan, S.,
    2. Stevens, M. and
    3. Wiley, J. W.
    (2000). Diabetic peripheral neuropathy: evidence for apoptosis and associated mitochondrial dysfunction. Diabetes 49, 1932-1938. doi:10.2337/diabetes.49.11.1932
    OpenUrlAbstract
  59. ↵
    1. Sullivan, K. A.,
    2. Hayes, J. M.,
    3. Wiggin, T. D.,
    4. Backus, C.,
    5. Su Oh, S.,
    6. Lentz, S. I.,
    7. Brosius, F. III. and
    8. Feldman, E. L.
    (2007). Mouse models of diabetic neuropathy. Neurobiol. Dis. 28, 276-285. doi:10.1016/j.nbd.2007.07.022
    OpenUrlCrossRefPubMedWeb of Science
  60. ↵
    1. To, M.,
    2. Goz, A.,
    3. Camenzind, L.,
    4. Oertle, P.,
    5. Candiello, J.,
    6. Sullivan, M.,
    7. Henrich, P. B.,
    8. Loparic, M.,
    9. Safi, F.,
    10. Eller, A. et al.
    (2013). Diabetes-induced morphological, biomechanical, and compositional changes in ocular basement membranes. Exp. Eye Res. 116, 298-307. doi:10.1016/j.exer.2013.09.011
    OpenUrlCrossRefPubMedWeb of Science
  61. ↵
    1. Tosaki, T.,
    2. Kamiya, H.,
    3. Yasuda, Y.,
    4. Naruse, K.,
    5. Kato, K.,
    6. Kozakae, M.,
    7. Nakamura, N.,
    8. Shibata, T.,
    9. Hamada, Y.,
    10. Nakashima, E. et al.
    (2008). Reduced NGF secretion by Schwann cells under the high glucose condition decreases neurite outgrowth of DRG neurons. Exp. Neurol. 213, 381-387. doi:10.1016/j.expneurol.2008.06.017
    OpenUrlCrossRefPubMedWeb of Science
  62. ↵
    1. Unsicker, K.,
    2. Skaper, S. D.,
    3. Davis, G. E.,
    4. Manthorpe, M. and
    5. Varon, S.
    (1985). Comparison of the effects of laminin and the polyornithine-binding neurite promoting factor from RN22 Schwannoma cells on neurite regeneration from cultured newborn and adult rat dorsal root ganglion neurons. Brain Res. 17, 304-308. doi:10.1016/0165-3806(85)90161-0
    OpenUrlCrossRef
  63. ↵
    1. Vincent, A. M. and
    2. Feldman, E. L.
    (2007). Can drug screening lead to candidate therapies for testing in diabetic neuropathy? Antioxid. Redox Signal. 10, 387-394. doi:10.1089/ars.2007.1815
    OpenUrlCrossRef
  64. ↵
    1. Vincent, A. M.,
    2. Russell, J. W.,
    3. Low, P. and
    4. Feldman, E. L.
    (2004). Oxidative stress in the pathogenesis of diabetic neuropathy. Endocr. Rev. 25, 612-628. doi:10.1210/er.2003-0019
    OpenUrlCrossRefPubMedWeb of Science
  65. ↵
    1. Vincent, A. M.,
    2. Mclean, L. L.,
    3. Backus, C. and
    4. Feldman, E. L.
    (2005). Short-term hyperglycemia produces oxidative damage and apoptosis in neurons. FASEB J. 19, 1-24. doi:10.1096/fj.04-2513fje
    OpenUrlCrossRefPubMed
  66. ↵
    1. Vincent, A. M.,
    2. Edwards, J. L.,
    3. McLean, L. L.,
    4. Hong, Y.,
    5. Cerri, F.,
    6. Lopez, I.,
    7. Quattrini, A. and
    8. Feldman, E. L.
    (2010). Mitochondrial biogenesis and fission in axons in cell culture and animal models of diabetic neuropathy. Acta Neuropathol. 120, 477-489. doi:10.1007/s00401-010-0697-7
    OpenUrlCrossRefPubMedWeb of Science
  67. ↵
    1. Volmer-Thole, M. and
    2. Lobmann, R.
    (2016). Neuropathy and diabetic foot syndrome. Int. J. Mol. Sci. 17, 917. doi:10.3390/ijms17060917
    OpenUrlCrossRefPubMed
  68. ↵
    1. Yurchenco, P. D.
    (2011). Basement membranes: cell scaffoldings and signaling platforms. Cold Spring Harb. Perspect. Biol. 3, a004911. doi:10.1101/cshperspect.a004911
    OpenUrlAbstract/FREE Full Text
  69. ↵
    1. Zherebitskaya, E.,
    2. Akude, E.,
    3. Smith, D. R. and
    4. Fernyhough, P.
    (2009). Development of selective axonopathy in adult sensory neurons isolated from diabetic rats: role of glucose-induced oxidative stress. Diabetes 58, 1356-1364. doi:10.2337/db09-0034
    OpenUrlAbstract/FREE Full Text
  70. ↵
    1. Zhou, J. and
    2. Zhou, S.
    (2014). Inflammation: therapeutic targets for diabetic neuropathy. Mol. Neurobiol. 49, 536-546. doi:10.1007/s12035-013-8537-0
    OpenUrlCrossRefPubMed
Back to top

RSSRSS

Keywords

 Download PDF

Email
RESEARCH ARTICLE
Sensory neuron cultures derived from adult db/db mice as a simplified model to study type-2 diabetes-associated axonal regeneration defects
Cristian De Gregorio, Fernando Ezquer
Disease Models & Mechanisms 2021 14: dmm046334 doi: 10.1242/dmm.046334 Published 22 January 2021
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
Citation Tools
Alerts

Article navigation

Subject collections

Other journals from The Company of Biologists

Advertisement

DMM and COVID-19

We are aware that the COVID-19 pandemic is having an unprecedented impact on researchers worldwide. The Editors of all The Company of Biologists’ journals have been considering ways in which we can alleviate concerns that members of our community may have around publishing activities during this time. Read about the actions we are taking at this time.

Please don’t hesitate to contact the Editorial Office if you have any questions or concerns.

The twin pillars of Disease Models & Mechanisms

In her first Editorial as Editor-in-Chief, Liz Patton sets out her vision and priorities for DMM focusing on four thematic challenges: mechanisms of disease, innovative technologies, disease progression through time and therapy.

Extended deadline - The RAS Pathway: Diseases, Therapeutics and Beyond

Our upcoming special issue is welcoming submissions until 3 May 2021. Guest-edited by Donita Brady (Perelman School of Medicine at the University of Pennsylvania, USA) and Arvin Dar (Icahn School of Medicine at Mount Sinai, USA), the issue will focus on the targeting the RAS pathway.

Find out more about the issue and how to submit your manuscript.

Perspective - Modelling the developmental origins of paediatric cancer to improve patient outcomes

James Amatruda authors our first Perspective, discussing some of the key challenges in paediatric cancer from his perspective as a physician-scientist.

A muscle growth-promoting treatment based on the attenuation of activin/myostatin signalling results in long-term testicular abnormalities

In this issue’s Editor’s choice, Ketan Patel and colleagues describe how even brief exposure to muscle-growth-promoting treatments exerts a long-term detrimental effect on the testes, and test promising therapeutics to mitigate this side-effect.